BioSpace News Archive

Science 37 Holdings, Inc. today announced it will report fourth quarter and full year 2021 financial results before the market opens on Tuesday, March 22, 2022.

Amedisys, Inc. announced that Chris Gerard, President and Chief Operating Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer, will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16 at 10:40 a.m. EST and at the Barclays Global Healthcare Conference on March 17 at 8:00 a.m. EST.

Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced it will be participating in the Oppenheimer 32nd Annual Virtual Healthcare Conference and the Maxim 2022 Virtual Growth Conference.

Monopar Therapeutics Inc. announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference.

X4 Pharmaceuticals, Inc. announced that it will report its financial results for the fourth quarter ended December 31, 2021, and provide an update on recent business highlights, on March 17, 2022.

Women’s Brain Health Initiative and Brain Canada are pleased to announce that six exceptional research teams have been selected to receive a funding boost of $105,000 each through the Brain Canada-WBHI Expansion Grants: Considering Sex and Gender Program.

Baudax Bio, Inc. a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced initiation of a clinical study evaluating the safety and pharmacokinetics of ANJESO injection in pediatric patients following surgery.

Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, announced that the Company’s president and CEO, Lisa Ricciardi, will be participating at two upcoming conferences, details of which follow.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it will report fourth quarter 2021 financial results on Wednesday, March 16, 2022.